ClinicalTrials.gg
CompletedNCT03375502Updated May 14, 2021

A Study of MG1111 in Healthy Children

A Phase 2/3 interventional study of Varicella Vaccine in Healthy Children, sponsored by Green Cross Corporation. Completed at 1 site in Korea, Republic of. Open to participants aged 12 Months to 12 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-05-14.

Sponsored by Green Cross Corporation · Phase 2/3, Interventional, and Prevention

From the registry’s dates

  • Registered 1 year after the study started (first participant enrolled Nov 2016, registered Nov 2017).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
814
Allocation
Randomized
Ages
12 Months to 12 Years
Sex
All
01

Study summary

To assess the safety of MG1111 and to evaluate immunological non-inferiority of MG1111 versus comparator

02

Conditions studied

  • Healthy Children
03

In context

Lead sponsor

Green Cross Corporation is the lead sponsor of 63 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
12 Months to 12 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy children aged 12 months to 12 years.
  • Subjects or parent/legal representative willing to provide written and able to comply with the requirements for the study - Subject able to attend all scheduled visits and to comply with all study procedures
  • Negative history of Varicella and varicella vaccine
  • Subject in good health, based on medical history and physical examination

Exclusion criteria

Exclusion Criteria:

  • Subjects who have a history of Varicella or administration of varicella vaccine
  • Subjects who have ahd an acute febrile episode at some time during the 72 hours before administration of product or those who had any symptom suspected to be allergy including systemic rash.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
814 participants (actual)

Study arms

  • Experimental
    MG1111(Varicella vaccine)

    A single injection of 0.5ml MG1111 will be administered subcutaneously at Visit 1

    Drug: Varicella Vaccine

  • Active comparator
    Comparator(Varicella vaccine)

    A single injection of 0.5ml comparator will be administered subcutaneously at Visit 1

    Drug: Varicella Vaccine

Interventions

  • The subject will receive investigational product or comparator.

    Also known as: vaccination

06

What researchers measure

Primary outcomes

  1. Proportion of subjects who achieved seroconversion

    Time frame: 42 days after vaccination

Secondary outcomes

  1. Geometric mean titer(GMT) measured by the FAMA assay

    Time frame: At day 0 and Day 42 post-vaccination

  2. Geometric mean titer(GMT) measured by gpELISA

    Time frame: At day 0 and Day 42 post-vaccination

Other outcomes

  1. Incidence of Local/systemic solicited AEs [Safety]

    Time frame: during the first 7 days after administration of IP

  2. Incidence of Unsolicited AEs [Safety]

    Time frame: Until Day 42 after administration of IP

  3. Incidence of Serious adverse events [Safety]

    Time frame: Until 6 months after administration of IP

07

Study locations

1 site
  • The catholic university of Korea, Seoul st. mary's hospital
    Banpo-dong, Seoul, Korea, Republic of
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Nov 2016 to primary completion in Jan 2019, 26 months.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 28, 2017
First posted
Dec 18, 2017
StartActual
Nov 26, 2016
Primary completionActual
Jan 29, 2019
CompletionActual
Jul 31, 2019
Last update
May 14, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 14, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03375502
Responsible party
Sponsor
First posted
Dec 18, 2017
Start date
Nov 26, 2016
Primary completion
Jan 29, 2019
Completion
Jul 31, 2019
Last update
May 14, 2021
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Chickenpox Vaccine

Start the discussion